Molecular basis for vaccine development against the ehrlichial pathogen Anaplasma marginale.
about
Complete genome sequencing of Anaplasma marginale reveals that the surface is skewed to two superfamilies of outer membrane proteinsAnaplasmosis: focusing on host-vector-pathogen interactions for vaccine development.CD4(+) T lymphocytes from calves immunized with Anaplasma marginale major surface protein 1 (MSP1), a heteromeric complex of MSP1a and MSP1b, preferentially recognize the MSP1a carboxyl terminus that is conserved among strains.Rapid deletion of antigen-specific CD4+ T cells following infection represents a strategy of immune evasion and persistence for Anaplasma marginale.Anaplasma marginale type IV secretion system proteins VirB2, VirB7, VirB11, and VirD4 are immunogenic components of a protective bacterial membrane vaccine.Selective in vivo depletion of CD4(+) T lymphocytes with anti-CD4 monoclonal antibody during acute infection of calves with Anaplasma marginale.Antigenic variation of Anaplasma marginale: major surface protein 2 diversity during cyclic transmission between ticks and cattle.Major histocompatibility complex class II DR-restricted memory CD4(+) T lymphocytes recognize conserved immunodominant epitopes of Anaplasma marginale major surface protein 1a.Identification of novel antigenic proteins in a complex Anaplasma marginale outer membrane immunogen by mass spectrometry and genomic mapping.Subdominant antigens in bacterial vaccines: AM779 is subdominant in the Anaplasma marginale outer membrane vaccine but does not associate with protective immunity.Anaplasma marginale infection with persistent high-load bacteremia induces a dysfunctional memory CD4+ T lymphocyte response but sustained high IgG titersIdentification of Anaplasma marginale outer membrane protein antigens conserved between A. marginale sensu stricto strains and the live A. marginale subsp. centrale vaccine.Functional and immunological relevance of Anaplasma marginale major surface protein 1a sequence and structural analysis.Antigens and alternatives for control of Anaplasma marginale infection in cattle.Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale.Genome-wide screening and identification of antigens for rickettsial vaccine development.Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against Anaplasma marginale.Genetic diversity of anaplasma species major surface proteins and implications for anaplasmosis serodiagnosis and vaccine development.Genomic and proteomic approaches to vaccine candidate identification for Anaplasma marginale.Characterization of recombinant MSP5 Anaplasma marginale Havana isolateProtective immunity induced by immunization with a live, cultured Anaplasma marginale strain.Nanoparticle-Based Delivery of Anaplasma marginale Membrane Proteins; VirB9-1 and VirB10 Produced in the Pichia pastoris Expression SystemAdaptive immunity to Anaplasma pathogens and immune dysregulation: implications for bacterial persistence.IgG and IgG2 antibodies from cattle naturally infected with Anaplasma marginale recognize the recombinant vaccine candidate antigens VirB9, VirB10, and elongation factor-Tu.Cross-protection between geographically distinct Anaplasma marginale isolates appears to be constrained by limited antibody responses.Emergence of Anaplasma marginale antigenic variants during persistent rickettsemia.Interleukin-12 as an adjuvant promotes immunoglobulin G and type 1 cytokine recall responses to major surface protein 2 of the ehrlichial pathogen Anaplasma marginaleExpression of polymorphic msp1beta genes during acute anaplasma Marginale rickettsemia.Strain diversity in major surface protein 2 expression during tick transmission of Anaplasma marginale.Antigenic variation of Anaplasma marginale by expression of MSP2 mosaics.Cooperation of PD-1 and LAG-3 Contributes to T-Cell Exhaustion in Anaplasma marginale-Infected Cattle.Expression of major surface protein 2 variants with conserved T-cell epitopes in Anaplasma centrale vaccinatesAnaplasma phagocytophilum MSP4 and HSP70 Proteins Are Involved in Interactions with Host Cells during Pathogen Infection.Stochastic transmission of multiple genotypically distinct Anaplasma marginale strains in a herd with high prevalence of Anaplasma infection.Anaplasma marginale major surface protein 2 CD4+-T-cell epitopes are evenly distributed in conserved and hypervariable regions (HVR), whereas linear B-cell epitopes are predominantly located in the HVR.Identification of a T-Cell Epitope That Is Globally Conserved among Outer Membrane Proteins (OMPs) OMP7, OMP8, and OMP9 of Anaplasma marginale Strains and with OMP7 from the A. marginale subsp. centrale Vaccine Strain.Maintenance of antibody to pathogen epitopes generated by segmental gene conversion is highly dynamic during long-term persistent infection.Characterization of a phenotypically unique population of CD13+ dendritic cells resident in the spleen.Complete genome sequence of Anaplasma marginale subsp. centrale.Unraveling the immune regulatory mechanisms imposed by Anaplasma.
P2860
Q22066392-E7B6824A-41B1-4801-8A8F-D18EAFF79ACEQ33264059-0AD51839-957D-4AF2-B382-E5F48DD1398DQ33552798-38B481B5-AD44-4041-A85B-6623F1378520Q33626336-43B16FD7-E20F-4672-AC3D-26B78C34A8CEQ33676020-ADEEA1D1-F20B-452E-8D4C-B2349308107AQ33942066-D859224F-D44A-41D5-93EF-8B5063A4345FQ34007269-BCE36297-5617-4C83-BF17-36E6DE30EF7BQ34132762-EBCCB067-9316-4E14-AA66-308E79143D17Q34194642-34CDF9C3-7D61-474D-8EA5-0952B38C7C7FQ34431155-2ED2560F-2294-4615-B642-0586B7686316Q34431959-4E583401-BBD6-4E26-9A5E-3E6B0288AFF5Q34739801-3052C172-7B7B-4FA0-BA35-1F26E4223CBAQ34775635-39A1753B-1E29-4A85-BF99-15571735FCF2Q35558824-6361A44D-A298-456F-A61D-9FD5BF787DAEQ35665455-984D8169-7110-448B-967F-500EDCA90577Q35784657-231926D2-2A83-46FA-B3FF-203448A0D534Q35999402-F47BCE8C-A1FD-4283-9F81-987237AD0D16Q36257834-784C4899-E328-4933-814D-EE63EDDA96C7Q36383815-A87D9056-7B7A-44AD-B496-51C0543E94D3Q37159414-CF35405E-372B-481A-AC55-3A1246DA82F5Q37519264-B56C2ADF-EE87-4963-B194-B691B49532DBQ37594405-9715058F-EC4D-4CBE-84E5-23303CEF58BAQ37973905-FDFD2196-EF3A-42C6-B1FE-18062282BA42Q38878619-CF0D011F-C381-44DF-99B5-E173D3A75AE9Q39128415-C57E5EB1-17FE-4D93-96AC-B93DFA35715AQ39512700-EC63A981-1320-4CD3-AD38-ADE399AF1A45Q39513745-7248F0A0-084B-4FB2-93AF-82274596FFA0Q39515031-760F49E0-F917-4DE9-95B1-1856D787500FQ39515814-FB1FA5A3-F26E-4C0C-8861-4C2F615BCE78Q39516711-28314072-3C46-407E-B47D-F024D43FAC39Q39588896-CE51828E-8D1A-4528-9BDD-DA013C8C32F6Q39653807-4C6695CD-1BBA-41FB-A8E7-3415F71BBC7DQ40115716-D92290DF-D14B-4B77-9018-5F9629732255Q40284363-88718A17-EADC-4021-B6AA-009D406691B9Q40423118-1874E670-0BF7-49B6-8F3A-370ADE4B833FQ40842064-E6B67AB3-EF3D-4E28-BCAB-BD146B2B3A0BQ42093667-7027DBAA-BA4E-49DD-ABA9-8E96D08506AAQ42157560-D90AAC0B-8D15-493E-A74A-294EFCAF506EQ42721418-8241EA7B-FEF6-4A11-A2E1-E133003D41F5Q43081737-CD701D96-EBC8-4810-B728-9D3E5B5EB28D
P2860
Molecular basis for vaccine development against the ehrlichial pathogen Anaplasma marginale.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@ast
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@en
type
label
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@ast
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@en
prefLabel
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@ast
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@en
P2093
P1476
Molecular basis for vaccine de ...... pathogen Anaplasma marginale.
@en
P2093
P304
P356
10.1016/S0169-4758(99)01469-6
P577
1999-07-01T00:00:00Z